Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1488-1495

  Armand Lefèvre, Laurence ^a,b   Angebault, Cécile ^a,b   Barbier, François ^a,b   Hamelet, Emilie ^a   Defrance, Gilles ^a   Ruppé, Etienne ^a,b   Bronchard, Régis ^a   Lepeule, Raphaël ^b   Lucet, Jean Christophe ^a   Mniai, Assiya El ^a   Wolff, Michel ^a   Montravers, Philippe ^a   Plésiat, Patrick ^c   Andremont, Antoine ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEMASE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE CONTROL STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; FEMALE; GENOMICS; GENOTYPE; GRAM NEGATIVE BACTERIUM; HAFNIA ALVEI; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; COLON; ENTEROBACTERIACEAE; FEMALE; GENE EXPRESSION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 84874051309     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01823-12     Document Type: Article

References (50)

1. Bogaerts P, Rodriguez-Villalobos H, Laurent C, Deplano A, Struelens MJ, Glupczynski Y. 2009. Emergence of extended-spectrum-AmpCexpressing Escherichia coli isolates in Belgian hospitals. J. Antimicrob. Chemother. 63:1073-1075.
2. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159 -166.
3. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. 2010. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit. Care 14:R113. doi:10.1186/cc9062.
4. Miliani K, L'Heriteau F, Lacave L, Carbonne A, Astagneau P. 2011. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. J. Hosp. Infect. 77:343-347.
5. European Centre for Disease Prevention and Control. 2012. Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARSNet). European Centre for Disease Prevention and Control, Stockholm, Sweden. http://ecdc.europa.eu/en/ publications/Publications/antimicrobial-resistance-surveillance-europe-2011.pdf.
6. Huang H, Siehnel RJ, Bellido F, Rawling E, Hancock RE. 1992. Analysis of two gene regions involved in the expression of the imipenem-specific, outer membrane porin protein OprD of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 76:267-273.
7. Crowley B, Benedi VJ, Domenech-Sanchez A. 2002. Expression of SHV-2 beta-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob. Agents Chemother. 46:3679 -3682.
8. Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C. 2000. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J. Clin. Microbiol. 38:1048 -1052.
9. Armand-Lefevre L, Leflon-Guibout V, Bredin J, Barguellil F, Amor A, Pages JM, Nicolas-Chanoine MH. 2003. Imipenem resistance in Salmonella enterica serovar Wien related to porin loss and CMY-4 betalactamase production. Antimicrob. Agents Chemother. 47:1165-1168.
10. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P. 2010. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg. Infect. Dis. 16:1349 -1356.
11. Tato M, Coque TM, Baquero F, Canton R. 2010. Dispersal of carbapenemase blaVIM-1 gene associated with different Tn402 variants, mercury transposons, and conjugative plasmids in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:320 -327.
12. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47)pii=19045. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId-19045.
13. Giamarellou H, Poulakou G. 2009. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69:1879 -1901.
14. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H. 2010. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 50:364 -373.
15. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31:47-53.
16. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE!An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
17. Andremont A. 2003. Commensal flora may play key role in spreading antibiotic resistance. ASM News 69:601- 607.
18. Pultz MJ, Nerandzic MM, Stiefel U, Donskey CJ. 2008. Emergence and acquisition of fluoroquinolone-resistant gram-negative bacilli in the intestinal tracts of mice treated with fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 52:3457-3460.
19. Mereghetti L, Tayoro J, Watt S, Lanotte P, Loulergue J, Perrotin D, Quentin R. 2002. Genetic relationship between Escherichia coli strains isolated from the intestinal flora and those responsible for infectious diseases among patients hospitalized in intensive care units. J. Hosp. Infect. 52:43-51.
20. Lucet JC, Decre D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, Kosmann MJ, Regnier B. 1999. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a university hospital. Clin. Infect. Dis. 29:1411-1418.
21. American Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
22. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE, Infectious Diseases Society of America, American College of Critical Care Medecine, Society for Healthcare Epidemiology of America. 2001. Guidelines for the management of intravascular catheterrelated infections. Clin. Infect. Dis. 32:1249 -1272.
23. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group. 2010. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463- 474.
24. Ruppe E, Armand-Lefevre L, Lolom I, El Mniai A, Muller-Serieys C, Ruimy R, Woerther PL, Bilariki K, Marre M, Massin P, Andremont A, Lucet JC. 2011. Development of a phenotypic method for detection of fecal carriage of OXA-48-producing Enterobacteriaceae after incidental detection from clinical specimen. J. Clin. Microbiol. 49:2761-2762.
25. Hocquet D, Plesiat P, Dehecq B, Mariotte P, Talon D, Bertrand X. 2010. Nationwide investigation of extended-spectrum beta-lactamases, metallo- beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. Antimicrob. Agents Chemother. 54:3512-3515.
26. Vettoretti L, Floret N, Hocquet D, Dehecq B, Plesiat P, Talon D, Bertrand X. 2009. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 28:1217-1222.
27. Barbier F, Ruppe E, Giakkoupi P, Wildenberg L, Lucet J, Vatopoulos A, Wolff M, Andremont A. 2010. Genesis of a KPC-producing Klebsiella pneumoniae after in vivo transfer from an imported Greek strain. Euro Surveill. 15(1):pii=19457. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId- 19457.
28. Heritier C, Poirel L, Lambert T, Nordmann P. 2005. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:3198- 3202.
29. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase- mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:15-22.
30. Jarlier V, Nicolas MH, Fournier G, Philippon A. 1988. Extended broadspectrum beta-lactamases conferring transferable resistance to newer beta- lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867- 878.
31. Drieux L, Brossier F, Sougakoff W, Jarlier V. 2008. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin. Microbiol. Infect. 14(Suppl 1):90 -103.
32. Woerther PL, Angebault C, Jacquier H, Hugede HC, Janssens AC, Sayadi S, El Mniai A, Armand-Lefevre L, Ruppe E, Barbier F, Raskine L, Page AL, de Rekeneire N, Andremont A. 2011. Massive increase, spread, and exchange of extended spectrum beta-lactamase-encoding genes among intestinal Enterobacteriaceae in hospitalized children with severe acute malnutrition in Niger. Clin. Infect. Dis. 53:677- 685.
33. Skurnik D, Lasocki S, Bremont S, Muller-Serieys C, Kitzis MD, Courvalin P, Andremont A, Montravers P. 2010. Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. J. Med. Microbiol. 59: 115-119.
34. Healy M, Huong J, Bittner T, Lising M, Frye S, Raza S, Schrock R, Manry J, Renwick A, Nieto R, Woods C, Versalovic J, Lupski JR. 2005. Microbial DNA typing by automated repetitive-sequence-based PCR. J. Clin. Microbiol. 43:199 -207.
35. McCabe WR. 1973. Gram-negative bacteremia. Dis. Mon. 1973:1-38.
36. Le Gall JR, Lemeshow S, Saulnier F. 1993. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963.
37. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, Corvec S. 2010. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn. Microbiol. Infect. Dis. 66:1- 6.
38. Pena C, Guzman A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J. 2007. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenemresistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob. Agents Chemother. 51:1967-1971.
39. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359.
40. DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H. 2005. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillintazobactam therapy for intraabdominal infections. Antimicrob. Agents Chemother. 49:3217-3221.
41. Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. 2011. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn. Microbiol. Infect. Dis. 70:367-372.
42. Cavallo JD, Hocquet D, Plesiat P, Fabre R, Roussel-Delvallez M. 2007. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J. Antimicrob. Chemother. 59:1021-1024.
43. Walsh TR. 2010. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl 3):S8 -S14.
44. Mugnier PD, Poirel L, Naas T, Nordmann P. 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis. 16:35- 40.
45. Daikos GL, Karabinis A, Paramythiotou E, Syriopoulou VP, Kosmidis C, Avlami A, Gargalianos P, Tzanetou K, Petropoulou D, Malamou- Lada H. 2007. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int. J. Antimicrob. Agents 29:471- 473.
46. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y. 2011. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin. Infect. Dis. 52:848-855.
47. Stiefel U, Harmoinen J, Koski P, Kaariainen S, Wickstrand N, Lindevall K, Pultz NJ, Bonomo RA, Helfand MS, Donskey CJ. 2005. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice. Antimicrob. Agents Chemother. 49:5190 -5191.
48. Tarkkanen AM, Heinonen T, Jogi R, Mentula S, van der Rest ME, Donskey CJ, Kemppainen T, Gurbanov K, Nord CE. 2009. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob. Agents Chemother. 53:2455-2462.
49. Khoder M, Tsapis N, Huguet H, Besnard M, Gueutin C, Fattal E. 2009. Removal of ciprofloxacin in simulated digestive media by activated charcoal entrapped within zinc-pectinate beads. Int. J. Pharm. 379:251-259.
50. Baquero F, Coque TM, de la Cruz F. 2011. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob. Agents Chemother. 55:3649 -3660.